oral glp 1 drugs in development GLP-1-Based Therapeutics the Obesity–Metabolic Syndrome–Diabetes Continuum: Translational Advances, Clinical Barriers, and Emerging Strategies The Chase for Novel Oral
Description
Regular follow-up to monitor glycemic control, weight, renal function, and tolerability is essential for optimizing therapeutic outcomes
Author contributions LD: Writing original draft, Visualization, Investigation
Sandberg, L
A., Mahmood, M
A few RCTs have investigated the effects of pioglitazone on cognitive decline in patients with AD [33,34,35,36]
Abbreviations: AMD, age-related macular degeneration
